Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)Srđan Verstovšek, Josef T. Prchal, Mohamed E. Salama et al.|Blood|2013Cited by 24